Hyperthermia and ablation system developer BSD Medical has completed the sale of its fourth BSD-2000 hyperthermia system to Taiwanese distributor Linden Bioscience.
Linden has purchased four of the devices since BSD Medical received Taiwan Food and Drug Administration (TFDA) marketing approval in February, according to the firm.
BSD-2000 delivers localized therapeutic heating by applying radiofrequency energy to tumors. It has humanitarian device exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy, BSD Medical said.
